However, with the potential inclusion of the HER2-low category among breast cancer predictive factors, future efforts should be addressed on determining the reliability of information obtained from core-needle-biopsy with respect to the surgical specimen in terms of both specificity and sensitivity. This evidence concerns the gene ERBB2 and breast cancer.